[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Evi Liliek Wulandari\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100612894",false,"NCT07259512","Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure","Comparative Effects of Single Versus Twice-Daily Ramipril Dosing on Renal Function in Patients With Chronic Kidney Disease and Heart Failure With Reduced Ejection Fraction: Evaluation of Plasma Renin Activity, Malondialdehyde, Interleukin-6, Albuminuria, and Cystatin C","Inclusion Criteria:\n\n* Female or Male with age \\>18 years old\n* Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction \\\u003C 40%)\n\nExclusion Criteria:\n\n* Receiving hemodialysis therapy\n* History of intolerance to ACE inhibitors\n* Refractory hyperkalemia\n* Pregnancy\n* History of angioedema to ACE inhibitors\n* Receiving sacubitril-valsartan therapy\n* Receiving ARB therapy\n* Hypotension with blood pressure \\\u003C90\u002F60, or patients in shock.","ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.",[25,26],"Chronic Kidney Disease","Heart Failure With Reduced Ejection Fraction (HFrEF)",[25,28,29],"HFrEF","Ramipril","RECRUITING","2025-12-02",{"date":33,"type":34},"2025-12-10","ACTUAL",{"date":36,"type":34},"2025-06-30",{"date":38,"type":19},"2026-01-31",{"name":40,"class":41},"Evi Liliek Wulandari","OTHER",""]